

GLAXOSMITHKLINE PLC

Form 6-K

January 17, 2017

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934

For period ending 16 January 2017

GlaxoSmithKline plc

(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS

(Address of principal executive offices)

Indicate by check mark whether the registrant files or  
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F  Form 40-F

--

Indicate by check mark whether the registrant by furnishing the  
information contained in this Form is also thereby furnishing the  
information to the Commission pursuant to Rule 12g3-2(b) under the  
Securities Exchange Act of 1934.

Yes  No

GlaxoSmithKline plc (the 'Company')

Transaction notification

1. Details of PDMR/person closely associated with them ('PCA')

- a) Name Sir Andrew Witty
- b) Position/status Chief Executive Officer
- c) Initial notification/ amendment Initial notification

Details of the issuer, emission allowance market

2. participant, auction platform, auctioneer or auction monitor

- a) Name GlaxoSmithKline plc
- b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a) the financial instrument	Description of	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882	
b) the transaction	Nature of	Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 January 2017 on Ordinary Shares held in the Company's 2009 Performance Share Plan.	
c) Price(s) and volume(s)	Price(s)	Volume(s)	
	£15.66	230.984	
	£15.66	4.229	
	£15.66	1414.139	
	£15.66	4242.446	
	£15.66	5799.902	

£15.66 6281.971

£15.66 617.137

Aggregated information  
 d) Aggregated volume 18,590.808  
 Price £15.66

Date of  
 e) the transaction 2017-01-12

Place  
 f) of the transaction n/a

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Ms E Walmsley

b) Position/status CEO Designate

c) Initial notification/ amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name GlaxoSmithKline plc

b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

Description of  
 a) the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')  
 ISIN: GB0009252882

b) Nature of Increase in notional interest in Ordinary Shares following

the transaction the re-investment of dividends paid to shareholders on 12 January 2017 on Ordinary Shares held in the Company's 2009 Performance Share Plan.

Price(s) Volume(s)

£15.66 1470.538

c) Price(s) and volume(s) £15.66 1507.800

£15.66 781.531

£15.66 2574.033

Aggregated information

d) A aggregated volume Price 6,333.902 £15.66

e) Date of the transaction 2017-01-12

f) Place of the transaction n/a

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Mr S Dingemans

b) Position/status Chief Financial Officer

c) Initial notification/ amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name GlaxoSmithKline plc

b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)	Description of the financial instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882	
b)	Nature of the transaction	Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 January 2017 on Ordinary Shares held in the Company's 2009 Performance Share Plan.	
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		£15.66	2489.181
		£15.66	2552.244
		£15.66	2764.183
d)	Aggregated information Aggregated volume Price	7,805.608 £15.66	
e)	Date of the transaction	2017-01-12	
f)	Place of the transaction	n/a	

1. Details of PDMR/person closely associated with them ('PCA')

a)	Name	Mr R G Connor
b)	Position/status	President, Global Manufacturing & Supply

c) Initial notification/  
amendment Initial notification

Details of the issuer, emission allowance market

2. participant, auction platform, auctioneer or  
auction monitor

a) Name GlaxoSmithKline plc

b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be  
repeated for (i) each type of instrument; (ii) each  
type of transaction; (iii) each date; and (iv) each  
place where transaction(s) has been conducted

Description  
of  
a) the  
financial  
instrument Ordinary shares of 25 pence  
each ('Ordinary Shares')  
ISIN: GB0009252882

Nature  
of  
b) the  
transaction Increase in notional interest  
in Ordinary Shares following  
the re-investment of  
dividends paid to  
shareholders on 12 January  
2017 on Ordinary Shares held  
in the Company's 2009  
Performance Share Plan.

	Price(s)	Volume(s)
c) Price(s) and volume(s)	£15.66	1144.520
	£15.66	1173.521
	£15.66	1503.083

Aggregated  
information  
d) Aggregated  
volume  
Price 3,821.124  
£15.66

Date of  
e) the  
transaction 2017-01-12

f) Place  
of n/a

the transaction

1. Details of PDMR/person closely associated with them ('PCA')

- a) Name                      Mr L Debruyne
- b) Position/status        President, Global Vaccines  
GSK
- c) Initial notification/  
amendment                Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

- a) Name                      GlaxoSmithKline plc
- b) LEI                        5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

- a) Description of the financial instrument                Ordinary shares of 25 pence each ('Ordinary Shares')  
ISIN: GB0009252882
- b) Nature of the transaction                        Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 January 2017 on Ordinary Shares held in the Company's 2009 Performance Share Plan.

	Price(s)	Volume(s)
c) Price(s) and volume(s)	£15.66	327.328
	£15.66	300.181
	£15.66	378.346
d) Aggregated		1,005.855

information £15.66  
 Aggregated  
 volume  
 Price

Date of  
 e) the 2017-01-12  
 transaction

Place  
 f) of n/a  
 the transaction

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Mr N Hirons

b) Position/status SVP, Global Ethics & Compliance

c) Initial notification/  
 amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name GlaxoSmithKline plc

b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

Description  
 of  
 a) the Ordinary shares of 25 pence  
 financial each ('Ordinary Shares')  
 instrument ISIN: GB0009252882

b) Nature Increase in notional interest  
 of in Ordinary Shares following  
 the the re-investment of  
 transaction dividends paid to  
 shareholders on 12 January  
 2017 on Ordinary Shares held  
 in the Company's 2009



Performance Share Plan.

	Price(s)	Volume(s)
c) Price(s) and volume(s)	£15.66	568.982
	£15.66	620.023

d) Aggregated information	1,189.005
d) Aggregated volume	£15.66
Price	

e) Date of the transaction	2017-01-12
----------------------------	------------

f) Place of the transaction	n/a
-----------------------------	-----

1. Details of PDMR/person closely associated with them ('PCA')

a) Name	Mr S A Hussain
b) Position/status	President, Global Pharmaceuticals
c) Initial notification/ amendment	Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name	GlaxoSmithKline plc
b) LEI	5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a) Description of the financial	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
---------------------------------	----------------------------------------------------------------------------

instrument

b) Nature of the transaction  
 Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 January 2017 on Ordinary Shares held in the Company's 2009 Performance Share Plan.

Price(s)      Volume(s)

c) Price(s) and volume(s)  
 £15.66      2310.737  
 £15.66      2667.111  
 £15.66      3006.180

d) Aggregated information  
 Aggregated volume      7,984.028  
 Price      £15.66

e) Date of the transaction  
 2017-01-12

f) Place of the transaction  
 n/a

1. Details of PDMR/person closely associated with them ('PCA')

a) Name      Mr D S Redfern  
 b) Position/status      Chief Strategy Officer  
 c) Initial notification/ amendment      Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name      GlaxoSmithKline plc  
 b) LEI      5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)	Description of the financial instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882	
b)	Nature of the transaction	Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 January 2017 on Ordinary Shares held in the Company's 2009 Performance Share Plan.	
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		£15.66	821.621
		£15.66	933.481
		£15.66	1089.729
d)	Aggregated information Aggregated volume Price	2,844.831 £15.66	
e)	Date of the transaction	2017-01-12	
f)	Place of the transaction	n/a	

1. Details of PDMR/person closely associated with them ('PCA')

a)	Name	Ms C Thomas
b)	Position/status	SVP, HR

c) Initial notification/  
amendment Initial notification

Details of the issuer, emission allowance market

2. participant, auction platform, auctioneer or  
auction monitor

a) Name GlaxoSmithKline plc

b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be  
repeated for (i) each type of instrument; (ii) each  
type of transaction; (iii) each date; and (iv) each  
place where transaction(s) has been conducted

Description  
of  
a) the financial instrument Ordinary shares of 25 pence  
each ('Ordinary Shares')  
ISIN: GB0009252882

Nature  
of  
b) the transaction Increase in notional interest  
in Ordinary Shares following  
the re-investment of  
dividends paid to  
shareholders on 12 January  
2017 on Ordinary Shares held  
in the Company's 2009  
Performance Share Plan.

	Price(s)	Volume(s)
c) Price(s)	£15.66	1172.271
and volume(s)	£15.66	1244.646
	£15.66	1371.559

Aggregated  
information  
d) A ggregated  
volume  
Price 3,788.476  
£15.66

e) Date of  
the transaction 2017-01-12

f) Place n/a

of  
the transaction

1. Details of PDMR/person closely associated with them ('PCA')

- a) Name                      Mr P C Thomson
- b) Position/status        SVP, Communications &  
Government Affairs
- c) Initial notification/  
amendment                Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

- a) Name                      GlaxoSmithKline plc
- b) LEI                        5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)	Description of the financial instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882	
b)	Nature of the transaction	Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 January 2017 on Ordinary Shares held in the Company's 2009 Performance Share Plan.	
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		£15.66	559.082
		£15.66	720.120
		£15.66	789.120

Aggregated information  
 d) Aggregated volume Price 2,068.322 £15.66

Date of  
 e) the transaction 2017-01-12

Place  
 f) of the transaction n/a

1. Details of PDMR/person closely associated with them ('PCA')

- a) Name Dr P J T Vallance
- b) Position/status President, R&D
- c) Initial notification/amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

- a) Name GlaxoSmithKline plc
- b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

- a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')  
 ISIN: GB0009252882
- b) Nature of the transaction Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 January 2017 on Ordinary Shares held in the Company's 2009

Performance Share Plan.

	Price(s)	Volume(s)
c) Price(s)	£15.66	2524.897
and volume(s)	£15.66	2588.867
	£15.66	3194.057

d) Aggregated information	8,307.821
Aggregated volume	£15.66
Price	

e) Date of the transaction	2017-01-12
----------------------------	------------

f) Place of the transaction	n/a
-----------------------------	-----

1. Details of PDMR/person closely associated with them ('PCA')

a) Name	Mrs V A Whyte
b) Position/status	Company Secretary
c) Initial notification/amendment	Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name	GlaxoSmithKline plc
b) LEI	5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a) Description of the	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
-----------------------	----------------------------------------------------------------------------

financial instrument			
b) Nature of the transaction	Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 January 2017 on Ordinary Shares held in the Company's 2009 Performance Share Plan.		
	Price(s)	Volume(s)	
c) Price(s) and volume(s)	£15.66	168.102	
	£15.66	159.405	
	£15.66	150.648	
d) Aggregated information Aggregated volume Price	478.155	£15.66	
e) Date of the transaction	2017-01-12		
f) Place of the transaction	n/a		

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc

(Registrant)

Date: January 16, 2017

By: VICTORIA WHYTE



-----  
Victoria Whyte

Authorised Signatory for and on

behalf of GlaxoSmithKline plc